1 / 33

Role of Cilostazol in Stroke Prevention

Philippine Heart Association 43 rd Annual Convention & Scientific Meeting Landmark Trials Session. Role of Cilostazol in Stroke Prevention. DANTE D. MORALES, MD,FPCP, FPCC. Crowne Plaza Manila Galleria. May 24, 2012. ESTABLISHED STROKE TREATMENT. Acute therapy for stroke

milton
Télécharger la présentation

Role of Cilostazol in Stroke Prevention

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Philippine Heart Association 43rd Annual Convention & Scientific Meeting Landmark Trials Session Role of Cilostazol in Stroke Prevention DANTE D. MORALES, MD,FPCP, FPCC Crowne Plaza Manila Galleria May 24, 2012

  2. ESTABLISHED STROKE TREATMENT • Acute therapy for stroke a. Anticoagulant and antiplatelets b. Thrombolytic 2. Secondary Prevention a. Antiplatelet agents b. Anticoagulants 3. Risk factor management

  3. Secondary Stroke Prevention • Anticoagulants a. WARRS Trial 2. Antiplatelets a. clopidogrel plus ASA (SPS3) b. cilostazol (CSPS 1&2)

  4. Secondary Stroke Prevention • Anticoagulants a. WARRS Trial 2. Antiplatelets a. clopidogrel plus ASA (SPS3) b. cilostazol (CSPS 1&2)

  5. Warfarinvs Aspirin WARRS trial - 4 RCTs of oral anticoagulants vsantiplatelet Rx in 1,870 patients with previous stroke Result: No difference in stroke recurrence nor major bleeding between Warfarin with INR 2.1 -3.6 and antiplatelet Aspirin Source: Cochrane Review, In:The Cochrane Library, Issue 1 2002

  6. Secondary Stroke Prevention • Anticoagulants a. WARRS Trial 2. Antiplatelets a. clopidogrel plus ASA (SPS3) b. cilostazol (CSPS 1&2)

  7. 2 X 2 Factorial design • Group I Clopidogrel 75mg+ ASA 325mg • Group II ASA 325mg + placebo • Group III BP control <130mm Hg • Group IV BP control 130-149mm Hg

  8. SPS 3 status • As of August 2011, due to excess in bleeding and mortality in the clopidogrel+ASAarm, this group was stopped. • However the ASA+placeboand BP control arm proceeded as planned.

  9. Secondary Stroke Prevention • Anticoagulants a. WARRS Trial 2. Antiplatelets a. clopidogrel plus ASA (SPS3) b. cilostazol (CSPS 1&2)

  10. Secondary Stroke Prevention • Anticoagulants a. WARRS Trial 2. Antiplatelets a. clopidogrel plus ASA (SPS3) b. cilostazol (CSPS 1&2)

  11. The Aim of CSPS2 To establish non-inferiority of Cilostazol compared with Aspirin in preventing recurrence of stroke To evaluate efficacy and safety-related events, in patients with non-cardioembolic cerebral infarction Non-inferiority: the case that the value of upper limit of the 95% Cl of the HR for recurrence of stroke between Cilostazol and Aspirin is not more than 1.33

  12. CSPS 2 Study n = 1337 2557 patients with non cardioembolic stroke Cilostazol 100 mg BID R Aspirin 81 mg OD n = 1335 • Study design: A multi-center, double-blind, parallel-group, randomized, prospective comparative study • Primary endpoints: Occurrence of stroke (cerebral infarction, cerebral hemorrhage, or subarachnoid hemorrhage) • Secondary endpoints: Recurrence of cerebral infarction, Occurrence of ischemic cerebrovascular diseases (cerebral infarction or TIA), all-cause death angina pectoris, myocardial infarction, cardiac failure, or hemorrhage requiring hospitalization • Recruitment Period: December 2003 to October 2006 • Duration of treatment: Minimum of 1 year and maximum of 5 years

  13. Patient Selection Criteria: Main inclusion criteria • Patients in a stable condition within 182 days (26 weeks) after occurrence of cerebral infarction • Patients with infarct-related foci detected by CT scan or MRI • Patients age 20 to 80 years (inclusive)at the time of consent • Patients having nocardiac diseases possibly associated with cardiogenic cerebral embolism

  14. Patient Selection Criteria: Main exclusion criteria • Patients with hemorrhage or bleeding tendency • Patients with ischemic heart failure • Patients with peptic ulcer • Patients with severe blood disorders • Patients with severe hepatic or renal disorders • Patients with malignant neoplasm or who have received any therapy for malignant neoplasm within 5 years prior to study enrollment

  15. Baseline Characteristics (1)

  16. Baseline Characteristics (2)

  17. Occurrence of Primary Endpoint (Stroke) Criteria of non-inferiority: Upper limit of 95%Cl *:P-value was lower than significance level 0.0471 for hazard ratio≤1.33

  18. Incidence of Primary and Secondary endpoints

  19. Kaplan-Meier Plots for Occurrence of Stroke

  20. Kaplan-Meier Plots for Safety endpoints (Hemorrhagic Events)

  21. Conclusions of CSPS Clinical Meaning of CSPS • High quality of evidence by large scale randomized study design (2557 patients) • Remarkable relative risk reduction of stroke recurrence (25.3%) • Safer antiplatelet choice with low risk of cerebralhemorrhage • This study, CSPS II, clearly demonstrated non-inferiority of cilostazol compared with aspirin in preventing recurrence of stroke. • Cilostazol was significantly more effective than aspirin in preventing recurrent stroke, with fewer hemorrhagic events. • Therefore, cilostazol is recommended as an option for the prevention of stroke recurrence in non-cardioembolic stroke patients who can tolerate long term administration of this drug • Subgroup analysis and cost-effectiveness analysis are still on going . Conclusions

  22. Thank you!

  23. MATCH Bleeding Events Adding aspirin to clopidogrel resulted in significantly more bleeding complications than clopidogrel arm, doubling the number of events. Lancet 2004;364:331-37

  24. MATCH: increased bleeding complications on clopidogrel + ASA compared to clopidogrelmonotherapy p<0.0001 for all BENEFIT ARR=0.5% NNT=200 BLEEDING (all) ARI=4.8% NNH=21 Diener et al. Lancet 2004; 364: 331–337.

  25. CHARISMA • Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic Events

  26. CHARISMA trial design Clopidogrel 75 mg/day (n=7802) Patients age ≥45 years at high risk for atherothrombotic events Low-dose ASA 75-162 mg/day R Double-blind treatment up to 1040 primary efficacy events* (n=15 603) Low-dose ASA 75-162 mg/day Placebo 1 tablet/day (n=7801) Final visit (fixed study end date) Visits every 6 months 1-month visit 3-month visit * MI (fatal or non-fatal), stroke (fatal or non-fatal), or cardiovascular death; event-driven trial Bhatt DL et al. Am Heart J 2004; 148: 263–268.

  27. Overall population: Primary and secondary efficacy results (MI/stroke/CV death/hospitalization)† Clopidogrel Placebo + ASA + ASA Endpoint* - n (%) (n=7802) (n=7801)RR (95% CI)pvalue Primary efficacy endpoint 534 (6.8) 573 (7.3) 0.93 (0.83,1.05) 0.22 All cause mortality 371 (4.8) 374 (4.8) 0.99 (0.86, 1.14) 0.90 CV mortality∆ 238 (3.1) 229 (2.9) 1.04 (0.87, 1.25) 0.68 Myocardial infarction (nonfatal)∆ 146 (1.9) 155 (2.0) 0.94 (0.75, 1.18) 0.59 Ischemic stroke (nonfatal) 132 (1.7) 163 (2.1) 0.81 (0.64, 1.02) 0.07 Stroke (nonfatal)∆ 150 (1.9) 189 (2.4) 0.79 (0.64, 0.98) 0.03 Principal secondary endpoint† 1301 (16.7) 1395 (17.9) 0.92 (0.86, 0.995) 0.04 Hospitalization‡ 866 (11.1) 957 (12.3) 0.90 (0.82, 0.98) 0.02 †First occurrence of MI (fatal or nonfatal), stroke (fatal or nonfatal), CV death (including hemorrhagic death), or hospitalization for UA, TIA, or revascularization *Intention-to-treat analysis ∆Components of the primary efficacy endpoint. Patients that did not die from CV causes, are counted for the first nonfatal event of MI or stroke. ‡For UA, TIA, or revascularization Bhatt DL et al. NEJM 2006.

More Related